CMAX BIOTECH CONSULTING: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CMAX BIOTECH CONSULTING
Largest movements
- Cash -€119,120
down €119,120 (-71.0%), from €167,671 to €48,551
mainly Other debts (-€71,246) and Contributions, distributions and other (-€59,500)
- Receivables within one year -€35,708
down €35,708 (-98.3%), from €36,338 to €630
of which Other amounts receivable: -€27,868
- Profit (loss) carried forward -€71,778
down €71,778 (-97.8%), from €73,424 to €1,646
- Other debts -€71,246
down €71,246 (-64.8%), from €109,968 to €38,723
- Trade debts -€9,652
down €9,652 (-99.7%), from €9,680 to €28
- Gross operating margin -€106,142
down €106,142, from €98,079 to -€8,063
- Taxes -€19,920
down €19,920 (-98.1%), from €20,301 to €381
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €206,772 | €52,078 | -€154,695 | -74.8% |
| Fixed assets | 21/28 | €2,763 | €2,897 | +€134 | +4.9% |
| Tangible fixed assets | 22/27 | €2,763 | €2,897 | +€134 | +4.9% |
| Plant, machinery and equipment | 23 | €368 | €708 | +€340 | +92.4% |
| Furniture and vehicles | 24 | €2,395 | €2,189 | -€206 | -8.6% |
| Current assets | 29/58 | €204,009 | €49,181 | -€154,829 | -75.9% |
| Amounts receivable within one year | 40/41 | €36,338 | €630 | -€35,708 | -98.3% |
| Trade receivables | 40 | €8,000 | €160 | -€7,840 | -98.0% |
| Other amounts receivable | 41 | €28,338 | €470 | -€27,868 | -98.3% |
| Cash at bank and in hand | 54/58 | €167,671 | €48,551 | -€119,120 | -71.0% |
| Total equity and liabilities | 10/49 | €206,772 | €52,078 | -€154,695 | -74.8% |
| Equity | 10/15 | €77,424 | €5,646 | -€71,778 | -92.7% |
| Contributions | 10/11 | €4,000 | €4,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €73,424 | €1,646 | -€71,778 | -97.8% |
| Amounts payable | 17/49 | €129,348 | €46,432 | -€82,916 | -64.1% |
| Amounts payable within one year | 42/48 | €129,348 | €46,432 | -€82,916 | -64.1% |
| Trade debts | 44 | €9,680 | €28 | -€9,652 | -99.7% |
| Suppliers | 440/4 | €9,680 | €28 | -€9,652 | -99.7% |
| Taxes, remuneration and social security | 45 | €9,700 | €7,681 | -€2,019 | -20.8% |
| Taxes | 450/3 | €9,700 | €7,681 | -€2,019 | -20.8% |
| Other amounts payable | 47/48 | €109,968 | €38,723 | -€71,246 | -64.8% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,273 | €1,845 | +€572 | +45.0% |
| Other operating charges | 640/8 | €507 | €921 | +€415 | +81.8% |
| Gross operating margin | 9900 | €98,079 | -€8,063 | -€106,142 | |
| Operating profit (loss) | 9901 | €96,300 | -€10,829 | -€107,129 | |
| Financial income | 75/76B | €192 | €0 | -€192 | -100% |
| Recurring financial income | 75 | €192 | €0 | -€192 | -100% |
| Financial charges | 65/66B | €1,327 | €1,068 | -€259 | -19.5% |
| Recurring financial charges | 65 | €1,327 | €1,068 | -€259 | -19.5% |
| Profit (loss) for the period before taxes | 9903 | €95,165 | -€11,897 | -€107,062 | |
| Income taxes | 67/77 | €20,301 | €381 | -€19,920 | -98.1% |
| Profit (loss) for the period | 9904 | €74,864 | -€12,278 | -€87,142 | |
| Profit (loss) for the period to be appropriated | 9905 | €74,864 | -€12,278 | -€87,142 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 27 October 2026 via checked.be.